Kura Oncology, Inc.KURAReports Tue, Nov 10 · Third Quarter 2026
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · kuraoncology.com
Kura Oncology is a clinical-stage biopharmaceutical company developing precision medicines for cancer, including menin inhibitors and farnesyl transferase inhibitors targeting genetically defined patient populations.
Key ratios
FCF / Sales
-152.1%TTM
2025
-104.8%2024
248.4%
Net margin
-208.5%TTM
ROA
-31.3%TTM
2025
-25.3%2024
-20.0%2023
-22.9%
ROE
-167.7%TTM
2025
-94.8%2024
-42.9%2023
-37.3%
Revenue growth
-7.3%TTM
2025
25.2%
Recent news
Kura Oncology to Report Third Quarter Financial Results on November 10
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
Track KURA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer